Linda Evangelista CoolSculpting Background
Linda Evangelista is a Canadian supermodel known for multiple high-profile campaigns and public statements about appearance changes. She has discussed CoolSculpting as a body-contouring option in interviews and public appearances. CoolSculpting is a noninvasive fat-reduction procedure developed by ZELTIQ Aesthetics, which was acquired by Allergan in 2017, and Allergan was later acquired by AbbVie in 2020. The procedure uses controlled cooling, a process called cryolipolysis, to target and reduce fat cells in specific areas of the body. The U.S. Food and Drug Administration has cleared CoolSculpting for visible fat reduction in certain areas, and the treatment is marketed as an alternative to liposuction for patients seeking non-surgical options. For background on Allergan and AbbVie, see the SEC filings and company pages such as SEC.gov and AbbVie.com.
The CoolSculpting procedure involves applying a device to the skin that cools fat tissue to a temperature that triggers apoptosis, or natural cell death, in fat cells. The body then processes and eliminates the dead fat cells over the weeks and months following treatment. Each session typically lasts around 35 to 60 minutes per area, and multiple sessions may be recommended depending on the patient's goals. The CoolSculpting system is manufactured by CoolSculpting, a brand under the broader medical aesthetics portfolio managed by AbbVie and its predecessor companies. The device is designed to target subcutaneous fat, the fat layer just beneath the skin, and is not intended for weight loss or obesity treatment. Clinical studies submitted to regulatory bodies have shown measurable reductions in fat layer thickness in treated areas.
CoolSculpting Procedure and Outcomes
Clinical data from CoolSculpting studies and real-world treatment reports indicate that patients can see a reduction of approximately 20 to 25 percent of fat in the treated area after one session. Results typically become noticeable within three weeks, with the most visible changes appearing after one to three months. The procedure is performed in outpatient medical spas and clinics by trained providers, and it does not require anesthesia or incisions. Common treatment areas include the abdomen, flanks, thighs, upper arms, and chin. Side effects are generally mild and temporary, including redness, swelling, bruising, and numbness in the treated area. Long-term outcomes depend on the patient's diet, exercise habits, and overall lifestyle. For more details on the procedure and clinical outcomes, see the CoolSculpting official page and medical resources such as CoolSculpting.com.
Linda Evangelista's public discussion of her CoolSculpting experience contributed to broader media coverage of the procedure and its visibility in celebrity culture. Her statements highlighted the noninvasive nature of the treatment and the expectation of gradual, natural-looking results. The case drew attention to the role of medical aesthetics in the broader beauty and wellness industry, which includes a range of non-surgical treatments such as injectables, laser therapies, and skin tightening. The financial impact of such treatments is significant, with the global medical aesthetics market valued in the tens of billions of dollars and growing steadily. CoolSculpting remains one of the leading noninvasive fat-reduction brands worldwide, with millions of procedures performed globally since its introduction. For market data and industry analysis, see reports from sources such as Forbes.com and Bloomberg.com.
Financial and Market Context
The CoolSculpting brand has been a significant revenue driver within AbbVie's aesthetics